Fortress Biotech Inc (FBIO)

$1.79

-0.04

(-2.19%)▲

Live

Performance

  • $1.75
    $1.82
    $1.79
    downward going graph

    2.51%

    Downside

    Day's Volatility :4.12%

    Upside

    1.65%

    downward going graph
  • $1.24
    $4.43
    $1.79
    downward going graph

    30.73%

    Downside

    52 Weeks Volatility :72.01%

    Upside

    59.59%

    downward going graph

Returns

PeriodFortress Biotech IncIndex (Russel 2000)
3 Months
-22.46%
0.0%
6 Months
4.57%
0.0%
1 Year
5.17%
0.0%
3 Years
-95.99%
-23.0%

Highlights

Market Capitalization
51.6M
Book Value
$0.79
Earnings Per Share (EPS)
-27.73
PEG Ratio
-0.1
Wall Street Target Price
14.0
Profit Margin
-49.25%
Operating Margin TTM
-168.76%
Return On Assets TTM
-36.41%
Return On Equity TTM
-1739.64%
Revenue TTM
82.6M
Revenue Per Share TTM
6.15
Quarterly Revenue Growth YOY
-14.299999999999999%
Gross Profit TTM
-85.7M
EBITDA
-90.3M
Diluted Eps TTM
-27.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.1
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-1.23

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Fortress Biotech Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 682.12%

Current $1.79
Target $14.00

Company Financials

FY18Y/Y Change
Revenue
26.9M
↓ 85.67%
Net Income
-84.1M
↑ 25.83%
Net Profit Margin
-313.02%
↓ 277.37%
FY19Y/Y Change
Revenue
36.6M
↑ 36.26%
Net Income
-51.8M
↓ 38.43%
Net Profit Margin
-141.44%
↑ 171.58%
FY20Y/Y Change
Revenue
45.6M
↑ 24.49%
Net Income
-103.0M
↑ 98.78%
Net Profit Margin
-225.85%
↓ 84.41%
FY21Y/Y Change
Revenue
68.8M
↑ 50.86%
Net Income
-164.8M
↑ 60.05%
Net Profit Margin
-239.6%
↓ 13.75%
FY22Y/Y Change
Revenue
75.7M
↑ 10.11%
Net Income
-213.9M
↑ 29.78%
Net Profit Margin
-282.42%
↓ 42.82%
FY23Y/Y Change
Revenue
84.5M
↑ 11.58%
Net Income
-60.6M
↓ 71.65%
Net Profit Margin
-71.75%
↑ 210.67%
Q1 FY23Q/Q Change
Revenue
12.4M
↓ 24.23%
Net Income
-22.1M
↓ 61.51%
Net Profit Margin
-177.9%
↑ 172.29%
Q2 FY23Q/Q Change
Revenue
17.4M
↑ 39.88%
Net Income
-24.8M
↑ 12.05%
Net Profit Margin
-142.51%
↑ 35.39%
Q3 FY23Q/Q Change
Revenue
34.8M
↑ 99.88%
Net Income
-5.0M
↓ 79.64%
Net Profit Margin
-14.52%
↑ 127.99%
Q4 FY23Q/Q Change
Revenue
19.9M
↓ 42.6%
Net Income
-9.3M
↑ 83.92%
Net Profit Margin
-46.52%
↓ 32.0%
Q1 FY24Q/Q Change
Revenue
13.0M
↓ 34.67%
Net Income
-17.7M
↑ 91.09%
Net Profit Margin
-136.08%
↓ 89.56%
Q2 FY24Q/Q Change
Revenue
14.9M
↑ 14.01%
Net Income
-13.3M
↓ 24.77%
Net Profit Margin
-89.79%
↑ 46.29%
FY18Y/Y Change
Total Assets
141.0M
↓ 42.67%
Total Liabilities
121.3M
↓ 3.35%
FY19Y/Y Change
Total Assets
226.4M
↑ 60.59%
Total Liabilities
153.9M
↑ 26.92%
FY20Y/Y Change
Total Assets
328.8M
↑ 45.23%
Total Liabilities
131.8M
↓ 14.33%
FY21Y/Y Change
Total Assets
396.5M
↑ 20.58%
Total Liabilities
170.6M
↑ 29.42%
FY22Y/Y Change
Total Assets
294.3M
↓ 25.78%
Total Liabilities
244.3M
↑ 43.16%
FY23Y/Y Change
Total Assets
167.5M
↓ 43.08%
Total Liabilities
165.9M
↓ 32.07%
Q1 FY23Q/Q Change
Total Assets
263.6M
↓ 10.45%
Total Liabilities
243.7M
↓ 0.22%
Q2 FY23Q/Q Change
Total Assets
180.7M
↓ 31.43%
Total Liabilities
196.7M
↓ 19.32%
Q3 FY23Q/Q Change
Total Assets
150.5M
↓ 16.69%
Total Liabilities
163.8M
↓ 16.71%
Q4 FY23Q/Q Change
Total Assets
167.5M
↑ 11.28%
Total Liabilities
165.9M
↑ 1.31%
Q1 FY24Q/Q Change
Total Assets
164.6M
↓ 1.72%
Total Liabilities
168.6M
↑ 1.59%
Q2 FY24Q/Q Change
Total Assets
145.7M
↓ 11.52%
Total Liabilities
160.3M
↓ 4.92%
FY18Y/Y Change
Operating Cash Flow
-98.8M
↑ 15.71%
Investing Cash Flow
18.8M
↓ 146.8%
Financing Cash Flow
50.6M
↓ 67.16%
FY19Y/Y Change
Operating Cash Flow
-95.0M
↓ 3.93%
Investing Cash Flow
20.1M
↑ 6.76%
Financing Cash Flow
146.7M
↑ 189.67%
FY20Y/Y Change
Operating Cash Flow
-83.7M
↓ 11.88%
Investing Cash Flow
-7.2M
↓ 135.65%
Financing Cash Flow
172.4M
↑ 17.51%
FY21Y/Y Change
Operating Cash Flow
-116.5M
↑ 39.27%
Investing Cash Flow
40.5M
↓ 665.52%
Financing Cash Flow
149.0M
↓ 13.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-43.2M
↓ 9.66%
Investing Cash Flow
-5.0M
↑ 0.0%
Financing Cash Flow
22.2M
↑ 19.17%
Q2 FY23Q/Q Change
Operating Cash Flow
-33.3M
↓ 22.97%
Investing Cash Flow
-2.0M
↓ 59.22%
Financing Cash Flow
-30.4M
↓ 236.93%

Technicals Summary

Sell

Neutral

Buy

Fortress Biotech Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fortress Biotech Inc
Fortress Biotech Inc
27.97%
4.57%
5.17%
-95.99%
-90.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fortress Biotech Inc
Fortress Biotech Inc
NA
NA
-0.1
-3.1
-17.4
-0.36
NA
0.79
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fortress Biotech Inc
Fortress Biotech Inc
Buy
$51.6M
-90.62%
NA
-49.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Fortress Biotech Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 13.03M → 14.85M (in $), with an average increase of 12.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -17.73M → -13.33M (in $), with an average increase of 32.9% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 84.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 140.8%

Institutional Holdings

  • Rosalind Advisors, Inc.

    2.21%

  • Vanguard Group Inc

    1.97%

  • Nantahala Capital Management, LLC

    1.11%

  • Shikiar Asset Management Inc

    0.86%

  • GSA Capital Partners LLP

    0.71%

  • Geode Capital Management, LLC

    0.47%

Company Information

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.

Organization
Fortress Biotech Inc
Employees
186
CEO
Dr. Lindsay Allan Rosenwald
Industry
Health Technology

Discover More

FAQs